Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

Authors: Nubia Muñóz, Ricardo Manalastas, Punee Pitisuttithum, Damrong Tresukosol, Joseph Monsonégo, Kevin A. Ault, Christine Clavel, Joaquín Luna, Evan R. Myers, Sara Hood, Oliver Bautista, Janine T. Bryan, Frank J. Taddeo, Mark T. Esser, Scott Vuocolo, Richard M. Haupt, Eliav Barr, Alfred J. Saah - The Lancet 2009 cited by 480